PERSPECTIVE THERAPEUTICS
LIVE

Serial Number

99900187

Owner

Perspective Therapeutics, Inc.

Attorney

Sandra L Etherton

Filing Date

Jun 23, 2026

Add to watchlist:

No watchlists yet
View on USPTO

PERSPECTIVE THERAPEUTICS Trademark

Serial Number: 99900187

PERSPECTIVE THERAPEUTICS is a trademark filed by Perspective Therapeutics, Inc. on June 23, 2026. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Perspective Therapeutics, Inc. (9 trademarks)

350 Hills St., Suite 106
Richland, WA 99354

Entity Type: 03

Trademark Details

Filing Date

June 23, 2026

Registration Date

Not Registered

Published for Opposition

October 20, 2026

Goods & Services

Active chemical ingredients for use in the manufacture of anti-cancer drugs; radiopharmaceutical chemical compounds for use in the manufacture of radiopharmaceutical preparations and anti-cancer drugs and for pharmaceutical research and development; radiolabeled chemical compounds comprising alpha-emitting radionuclides for use in the manufacture of radiopharmaceutical preparations and anti-cancer drugs and for pharmaceutical research and development; bifunctional chelating agents for conjugating radionuclides to targeting molecules for use in the manufacture of radiopharmaceutical preparations and anti-cancer drugs and for pharmaceutical research and development; chemical precursors for use in the manufacture of radiopharmaceuticals; chelating compounds for radiolabeling of peptides and small molecules; radioactive isotope-labeled chemical intermediates for pharmaceutical research and manufacturing

Medical and scientific research in the field of cancer treatment and diagnosis; scientific research and development services in the field of radiopharmaceuticals and nuclear medicine; scientific contract research services in the field of radiopharmaceutical drug discovery and development; preclinical research and development services relating to radiolabeled compounds for cancer therapy and diagnosis; scientific consultation services in the field of targeted radionuclide therapy; laboratory research services in the field of radiochemistry and radiopharmaceutical development; drug discovery research services in the field of oncology radiopharmaceuticals; scientific research and technological services relating to the development of targeted alpha therapy compounds; research and development services relating to theranostic radiopharmaceutical platforms

Pharmaceutical products for the treatment of cancer; radiopharmaceutical preparations for the treatment of cancer; radiopharmaceutical preparations for the diagnosis of cancer; targeted alpha therapy radiopharmaceutical preparations for the treatment of cancer comprising prostate cancer, breast cancer, pancreatic cancer, colorectal cancer, or neuroendocrine tumors; radioligand therapy preparations comprising radiolabeled targeting compounds for oncological use; radiopharmaceutical diagnostic agents for use in nuclear medicine imaging; radiopharmaceutical preparations for the treatment of cancers; radiolabeled peptide conjugates for use in cancer therapy; radiopharmaceutical preparations for theranostic applications in oncology

Filing History

APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 18, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 17, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 17, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 17, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 10, 2026 GNRN
NON-FINAL ACTION E-MAILED
Sep 10, 2026 GNRT
NON-FINAL ACTION WRITTEN
Sep 10, 2026 CNRT
ASSIGNED TO EXAMINER
Sep 9, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 23, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 23, 2026 NWOS
NEW APPLICATION ENTERED
Jun 23, 2026 NWAP